Shanghai Fudan-Zhangjiang Bio-pharmaceutical Co., Ltd. together with its subsidiaries, is engaged in the research, development and selling of self-developed, bio-pharmaceutical know-how, carrying out contracted research for customers, manufacturing and selling of medical products, and the provision of related ancillary services in the People鈥檚 Republic of China. The Company鈥檚 major technical platforms include Genetic Engineering drugs, Photodynamic therapy drugs and Liposome drugs. Its Genetic Engineering drugs related projects include recombinant tissue type plasminogen activator, Recombinant human parathyroid hormone derivatives, Recombinant human lymphotoxin 伪-derivatives, Recombinant human interleukin-1 receptor antagonist and Recombinant human tumor necrosis recipient Fc fusion protein. Its Photodynamic therapy drugs related projects include ALA, Hemoporfin and Duteroporphyrin. Liposome drugs related projects include Libod and Vincristine Liposome Injection.